EMA Guidance Brings Sharper Focus to Drug Delivery in Europe

Updated EMA guidance clarifies how drug-device products are regulated, shaping planning, partnerships, and investment priorities across Europe

2 Dec 2025

Europe’s drug delivery sector is adjusting to clearer regulatory expectations after the European Medicines Agency updated its guidance on medicines that incorporate or rely on delivery devices, influencing how companies plan development rather than triggering immediate dealmaking.

In December 2025, the EMA revised its Questions and Answers document on the application of EU medical device rules to combination products. The update clarifies how existing frameworks apply to medicines used with devices such as injection pens, inhalers and wearable injectors, and reinforces that these components form part of a product’s overall benefit-risk assessment.

The guidance underlines the need for developers to generate evidence against general safety and performance requirements earlier in a product’s lifecycle. Industry advisers say this is prompting pharmaceutical groups to consider delivery technologies alongside the drug itself, rather than treating devices as a later-stage addition.

Companies are increasingly favouring delivery platforms with established regulatory precedents and engaging device suppliers and service partners earlier to reduce uncertainty ahead of approval. Consultants describe a more deliberate approach to pathway design and risk management, rather than a sudden change in transaction activity.

Device manufacturers are adapting by placing greater emphasis on regulatory support, human factors engineering and patient use studies, alongside hardware development. Large medical technology groups have highlighted rising demand from pharmaceutical customers for early-stage assistance with compliance and validation, reflecting a shift in how services are positioned.

Broader market trends also support sustained attention on delivery systems. Industry forecasts point to continued growth in the global drug delivery device market through the end of the decade, driven by the expansion of biologic medicines, greater self-administration and care moving closer to the home. Europe is expected to remain an important market, particularly for injectable and connected devices.

Analysts say the clearer regulatory environment is shaping both investor and developer behaviour. Companies with proven, scalable delivery platforms are often seen as better placed to manage regulatory complexity, while smaller developers face higher evidentiary demands and are increasingly exploring partnerships to access specialist expertise and control costs.

Challenges remain, including higher upfront investment and pressure on regulatory review capacity. However, the EMA’s updated guidance is widely viewed as reducing ambiguity and supporting more informed decision-making, reinforcing the role of drug delivery devices as a central element of product strategy rather than an afterthought.